

## Clinical Policy: Facet Joint Interventions

Reference Number: CP.MP.171

Date of Last Revision: 07/22

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Chronic low back pain is frequently attributed to disorders of the facet joint. Neck pain related to whiplash injury is also thought to be related to the cervical zygapophyseal facet joint. However, the diagnosis of facet joint pain is difficult and often is based on pain relief following a diagnostic pain block of the medial branch of the posterior rami of the spinal nerve supplying the facet joint.

### Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that invasive pain management procedures performed by a physician are **medically necessary** when *the relevant criteria are met, and the patient receives only one procedure per visit, with or without radiographic guidance.*

- I. Facet Joint Injections, performed under fluoroscopy or computed tomographic (CT) guidance, are considered **medically necessary** for the following indications:
  - A. *Up to two\* controlled medial branch blocks/facet joint injections in the lumbar and cervical regions* when all the following criteria are met:
    1. Intermittent or continuous back or neck pain that interferes with activities of daily living (ADLs) has lasted for  $\geq 3$  months;
    2. The member/enrollee has failed to respond to conservative therapy including all of the following:
      - a.  $\geq 6$  weeks chiropractic, physical therapy or prescribed home exercise program;
      - b. Nonsteroidal anti-inflammatory drugs (NSAIDs)  $\geq 3$  weeks or NSAIDs contraindicated or not tolerated;
      - c.  $\geq 6$  weeks activity modification;
    3. Clinical findings suggest facet joint syndrome, and imaging studies suggest no other obvious cause of the pain (e.g., disc herniation, radiculitis, discogenic or sacroiliac pain). Physical findings of spinal facet joint syndrome can include low back pain exacerbated on extension and rotation; positive response to facet loading maneuvers or pain worse at night;
    4. No more than three spinal levels (unilateral or bilateral) are to be treated at the same session;
    5. If a second injection is required, it is performed at the same level(s) to confirm the validity of a positive clinical response (i.e.  $>75\%$  pain relief) to the initial injection, and the injections should be given at least 2 weeks apart;
    6. A radiofrequency joint denervation/ablation procedure is being considered.

\*Note: If the first controlled medial branch block/facet joint injection has  $< 75\%$  pain relief, a second block is **not medically necessary**.

## CLINICAL POLICY

### Facet Joint Interventions

- II.** *Facet joint medial branch conventional radiofrequency neurotomy* performed under fluoroscopy or computed tomographic (CT) guidance is considered **medically necessary** for the following indications:
- A.** *Initial facet joint medial branch conventional radiofrequency neurotomy in the lumbar or cervical region* is medically necessary when all of the following criteria are met:
1. Chronic neck or back pain is present;
  2. There was a positive response to two diagnostic controlled facet joint injections/medial branch blocks (at each region to be treated), as indicated by  $\geq 75\%$  pain relief with the ability to perform prior painful movements without significant pain;
  3. No more than three spinal levels (unilateral or bilateral) are to be treated at the same session.
- B.** *Repeat facet joint medial branch conventional radiofrequency neurotomy* performed under fluoroscopy or computed tomographic (CT) guidance in the lumbar or cervical regions is medically necessary when all the following criteria are met:
1. At least 6 months have elapsed since the previous treatment;
  2.  $\geq 50\%$  relief was obtained for at least 4 months, with associated functional improvement, following the previous treatment;
  3. No more than three spinal levels (unilateral or bilateral) are to be treated at the same session.
- III.** *Facet joint injections of the thoracic region* are considered **not medically necessary** because effectiveness has not been established.
- IV.** *Therapeutic facet joint injections* are considered **not medically necessary** because effectiveness has not been established.
- V.** *Conventional radiofrequency neurotomy of the facet joints of the thoracic region* is considered **not medically necessary** because effectiveness has not been established. There is a need for further well-designed, randomized controlled trials to evaluate effectiveness.
- VI.** *Pulsed radiofrequency neurotomy of the facet joints* is considered **not medically necessary**. The available evidence on the effectiveness of pulsed radiofrequency in the treatment of patients with various chronic pain syndromes is largely based on retrospective, case series studies. Its clinical value needs to be examined in well-designed, randomized controlled trials with large sample size and long-term follow-up. Studies on pulsed radiofrequency ablation continue to be done.

## Background

### *Facet Joint Injection*

Patients referred for facet injections most often have degenerative disease of the facet joints. However, even if the facet joint appears radiologically normal, facet injections still may be of use as radiologically occult synovitis can cause facet pain, particularly in younger patients. Post laminectomy syndrome, or nonradicular pain occurring after laminectomy, is also an acceptable reason to perform facet injections.

The body of evidence for facet joint injection equivocally supports the use of corticosteroids or local anesthetic for low back pain of facet joint origin, but questions remain regarding long-term safety, patient selection criteria, and comparative effectiveness versus standard therapies.<sup>1</sup> It is unclear whether improvements from facet joint injections last beyond three to six months.

Evidence is insufficient to support the use of facet joint injections for thoracic pain of facet joint origin, as only one randomized controlled trial has been conducted.<sup>1,17</sup>

It is recommended that facet joint interventions be performed under fluoroscopy or computed tomographic (CT) guidance.<sup>20</sup> The evidence evaluating ultrasound guidance for facet joint interventions is limited and inconclusive at this time.

*Facet Joint Radiofrequency Neurotomy*

Based on the outcome of a facet joint nerve block, if the patient gets sufficient relief of pain, but the pain recurs, one of the options is to denervate the facet joint. Radiofrequency neurotomy, also known as radiofrequency ablation, has been shown to temporarily reduce cervical and lumbar pain. Radiofrequency neurotomy involves delivering radio waves to targeted nerves via needles inserted through the skin. The heat created by the radio waves interferes with the nerves' ability to transmit pain signals.

Studies comparing pulsed radiofrequency neurotomy with conventional radiofrequency neurotomy have had low sample size and poor inclusion criteria.<sup>18</sup> Further research should be conducted to determine safety and efficacy of pulsed radiofrequency neurotomy for low back pain.<sup>8</sup>

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

**CPT codes that support coverage criteria**

CPT® Codes	Description
64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level
64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure)

<b>CPT® Codes</b>	<b>Description</b>
64492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level
64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)
64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)
64635	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint
64636	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)

**CPT codes that do not support coverage criteria**

<b>CPT® Codes</b>	<b>Description</b>
0213T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level
0214T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)
0215T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)

**CLINICAL POLICY**  
**Facet Joint Interventions**

CPT® Codes	Description
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)

HCPCS Codes	Description
N/A	

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

ICD 10 CM Code	Description
M43.11	Spondylolisthesis, occipito-atlanto-axial region
M43.12	Spondylolisthesis, cervical region
M43.16	Spondylolisthesis, lumbar region
M46.92	Unspecified inflammatory spondylopathy, cervical region
M46.96	Unspecified inflammatory spondylopathy, lumbar region
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region
M47.12	Other spondylosis with myelopathy, cervical region
M47.16	Other spondylosis with myelopathy, lumbar region
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region
M47.892	Other spondylosis, cervical region
M47.896	Other spondylosis, lumbar region
M51.36	Other intervertebral disc degeneration, lumbar region
M53.0	Cervicocranial syndrome
M53.1	Cervicobrachial syndrome
M53.81	Other specified dorsopathies, occipito-atlanto-axial region
M53.82	Other specified dorsopathies, cervical region
M53.86	Other specified dorsopathies, lumbar region
M54.2	Cervicalgia
M54.30 through M54.32	Sciatica
M54.40 through M54.42	Lumbago with sciatica
M54.5	Low back pain
M54.89	Other dorsalgia
M54.9	Dorsalgia, unspecified

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Reviewed in CP.MP.118 Injections for Pain Management: Added that injections are indicated in cervical and lumbar region.	04/18	04/18
Reviewed in CP.MP.118 Injections for Pain Management: Revised criteria to state the levels treated can be unilateral or bilateral	07/18	07/18
Policy split from CP.MP.118 Injections for Pain Management. Minor rewording for clarity.	09/18	
References reviewed and updated. Coding reviewed. Specialty review completed.	07/19	07/19
Moved A.1 to A.5 and clarified that injections must be 2 weeks apart if a second injection is required due to a lack of positive response.	11/19	
Clarified that facet joint injections of the thoracic region are not medically necessary in III, and reordered not medically necessary statements III-VI.	03/20	
Added to policy statements that interventions should be performed under fluoroscopy or computed tomographic (CT) guidance. Revised language in I.A. 5 for clarity. Added criteria I.A.6 requiring that radiofrequency joint denervation/ablation procedure is being considered. Added the following CPT codes as investigational: 0213T, 0214T, 0215T, 0216T, 0217T, and 0218T and noted in background that there is insufficient evidence to support US guided interventions. References reviewed and updated.	06/20	07/20
Annual review. References reviewed and reformatted for AMA style. Changed “review date” in the header to “date of last revision” and “date” in the revision log header to “revision date.” Replaced “member(s)” with “member(s)/enrollee(s)” throughout policy. Specialty review completed.	07/21	07/21
Annual review. Description updated to single spacing. Grammatical updates added to Description, first paragraph in Policy/Criteria and in Criteria I, II, V., and VI. Background updated with no impact on criteria. References reviewed and updated.	07/22	07/22

**References**

1. Health Technology Assessment. Intra-articular facet joint injections for the treatment of chronic nonmalignant spinal pain of facet joint origin. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published April 19, 2018 (annual review April 06, 2022). Accessed June 14, 2022.
2. Chou R, Hashimoto R, Friedly J, et al. *Pain Management Injection Therapies for Low Back Pain*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
3. Chou R. Subacute and chronic low back pain: Nonsurgical interventional treatment. UpToDate. [www.uptodate.com](http://www.uptodate.com). Accessed June 09, 2022.
4. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society [published correction appears in *Ann Intern Med*. 2008 Feb 5;148(3):247-8]. *Ann Intern Med*. 2007;147(7):478-491. doi:10.7326/0003-4819-147-7-200710020-00006

5. Chou R, Qaseem A, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians [published correction appears in *Ann Intern Med*. 2012 Jan 3;156(1 Pt 1):71]. *Ann Intern Med*. 2011;154(3):181-189. doi:10.7326/0003-4819-154-3-201102010-00008
6. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine (Phila Pa 1976)*. 2009;34(10):1066-1077. doi:10.1097/BRS.0b013e3181a1390d. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine (Phila Pa 1976)*. 2009;34(10):1066-1077. doi:10.1097/BRS.0b013e3181a1390d
7. Heggeness MH. AAOS endorses back pain guidelines. *AAOS Now*. <https://www.maine-general.org/app/files/public/6460f387-09dc-4968-b162-eee6121a1497/aaosbackpainguidelines.pdf>. Published September 2010. Accessed June 13, 2022.
8. Maas ET, Ostelo RW, Niemisto L, et al. Radiofrequency denervation for chronic low back pain. *Cochrane Database Syst Rev*. 2015;2015(10):CD008572. Published 2015 Oct 23. doi:10.1002/14651858.CD008572.pub2
9. Manchikanti L, Datta S, Derby R, et al. A critical review of the American Pain Society clinical practice guidelines for interventional techniques: part 1. Diagnostic interventions. *Pain Physician*. 2010;13(3):E141-E174.
10. Manchikanti L, Datta S, Gupta S, et al. A critical review of the American Pain Society clinical practice guidelines for interventional techniques: part 2. Therapeutic interventions. *Pain Physician*. 2010;13(4):E215-E264.
11. Soloman M, Mekhail MN, Mekhail N. Radiofrequency treatment in chronic pain. *Medscape Expert Rev Neurother*. 2010;10(3):469-474.
12. Staal JB, de Bie R, de Vet HC, Hildebrandt J, Nelemans P. Injection therapy for subacute and chronic low-back pain. *Cochrane Database Syst Rev*. 2008;2008(3):CD001824. Published 2008 Jul 16. doi:10.1002/14651858.CD001824.pub3
13. Manchikanti L, Kaye AD, Boswell MV, et al. A Systematic Review and Best Evidence Synthesis of the Effectiveness of Therapeutic Facet Joint Interventions in Managing Chronic Spinal Pain. *Pain Physician*. 2015;18(4):E535-E582.
14. Manchikanti L, Hirsch JA, Kaye AD, Boswell MV. Cervical zygapophysial (facet) joint pain: effectiveness of interventional management strategies. *Postgrad Med*. 2016;128(1):54-68. doi:10.1080/00325481.2016.1105092
15. McCormick ZL, Marshall B, Walker J, McCarthy R, Walega DR. Long-Term Function, Pain and Medication Use Outcomes of Radiofrequency Ablation for Lumbar Facet Syndrome. *Int J Anesth*. 2015;2(2):028. doi:10.23937/2377-4630/2/2/1028
16. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician*. 2013;16(2 Suppl):S49-S283.
17. Manchikanti L, Kaye AD, Sooin A, et al. Comprehensive Evidence-Based Guidelines for Facet Joint Interventions in the Management of Chronic Spinal Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines Facet Joint Interventions 2020 Guidelines. *Pain Physician*. 2020;23(3S):S1-S127

18. North American Spine Society: Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Low Back Pain. 2020.  
<https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf>. Accessed June 16, 2022.
19. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. *Reg Anesth Pain Med*. 2020;45(6):424-467. doi:10.1136/rapm-2019-101243

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

## CLINICAL POLICY

### Facet Joint Interventions

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.